HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The effect of acute respiratory distress syndrome on bone marrow-derived mesenchymal stem cells.

AbstractBACKGROUND:
It is known that, following a physiological insult, bone marrow-derived mesenchymal stem cells (MSCs) mobilize and home to the site of injury. However, the effect of injury on the function of endogenous MSCs is unknown. In this study, MSCs harvested from the bone marrow of swine with or without acute respiratory distress syndrome (ARDS) were assessed for their characteristics and therapeutic function.
METHODS:
MSCs were harvested from three groups of anesthetized and mechanically ventilated swine (n = 3 in each group): 1) no ARDS ('Uninjured' group); 2) ARDS induced via smoke inhalation and 40% burn and treated with inhaled epinephrine ('Injured Treated' group); and 3) ARDS without treatment ('Injured Untreated' group). Cellular evaluation of the three groups included: flow cytometry for MSC markers; colony forming unit-fibroblast (CFU-F) assay; proliferative and metabolic capacity; gene expression using quantitative real-time polymerase chain reaction (qRT-PCR); and a lipopolysaccharide (LPS) challenge, with or without coculture with mononuclear cells (MNCs), for evaluation of their protein secretion profile using Multiplex. Statistical analysis was performed using one- or two-way analysis of variance (ANOVA) with a Tukey's post-test; a p-value less than 0.05 was considered statistically significant.
RESULTS:
Cells from all groups exhibited nearly 100% expression of MSC surface markers and retained their multidifferentiation capacity. However, the MSCs from the 'Injured Untreated' group generated a significantly higher number of colonies compared with the other two groups (p < 0.0001), indicative of increased clonogenic capacity following ARDS. Following an LPS challenge, the MSCs from the 'Injured Untreated' group exhibited a significant reduction in their proliferative capacity (p = 0.0002), significant downregulation in the expression of high-mobility group box 1 (HMGB1; p < 0.001), Toll-like receptor (TLR)-4 (p < 0.01), and vascular endothelial growth factor (VEGF; p < 0.05) genes, and significantly diminished secretory capacity for the inflammatory mediators interleukin (IL)-6 (p < 0.0001), IL-8 (p < 0.05), and tumor necrosis factor (TNF)-α (p < 0.05) compared with the 'Uninjured' group.
CONCLUSIONS:
The results suggest that, following ARDS, there is an increase in the clonogenic capacity of MSCs to increase the available stem cell pool in vivo. However, MSCs harvested from subjects with ARDS seem to exhibit a diminished capacity to proliferate, express regenerative signals, and secrete pro/anti-inflammatory mediators.
AuthorsBen Antebi, Kerfoot P Walker 3rd, Arezoo Mohammadipoor, Luis A Rodriguez, Robbie K Montgomery, Andriy I Batchinsky, Leopoldo C Cancio
JournalStem cell research & therapy (Stem Cell Res Ther) Vol. 9 Issue 1 Pg. 251 (09 26 2018) ISSN: 1757-6512 [Electronic] England
PMID30257702 (Publication Type: Journal Article, Research Support, U.S. Gov't, Non-P.H.S.)
Chemical References
  • HMGB1 Protein
  • Lipopolysaccharides
  • Toll-Like Receptor 4
  • Tumor Necrosis Factor-alpha
Topics
  • Animals
  • Bone Marrow Cells (drug effects, pathology)
  • Coculture Techniques
  • Flow Cytometry
  • Gene Expression Regulation (drug effects)
  • HMGB1 Protein (genetics)
  • Lipopolysaccharides (pharmacology)
  • Mesenchymal Stem Cell Transplantation
  • Mesenchymal Stem Cells (pathology)
  • Respiratory Distress Syndrome (drug therapy, pathology)
  • Swine
  • Toll-Like Receptor 4 (genetics)
  • Tumor Necrosis Factor-alpha (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: